Free Download Zuma For Mac
Harriet Wehrenberg
The crux outputs max 24W (12V at 2A). The Ojai has 5 outputs (9V, 0.5A = 22.5W). So the crux is drawing more that what the zumma is designed for. Strymon did mention that the outputs can provide a bit more juice at 0.53A to account for any drops and that brings the total up to 23.85W which is still less the crux.
Strymon also mentioned that you could potentially overload the zuma if you maxed out all capacity of the outputs as well as connect an ojai and max out that too. Seeing as Im maxing out that 24V output and planning on using some other pedals I just wanted to check this is okay. I have about 15Watts worth of other pedals connects which is still below the overall power draw of the zuma (48W).
That being said, I emailed cioks and they also said that the crux is only designed for the DC7 and that they wouldnt take any responsibility or validate any warranty issues with it being used with the zuma.
TLDR: Is the cioks crux okay to use with the zumma? Neither company condones this set up or will validate the warranty and doing some quick maths, it seems like the crux is drawing what appears to be more than the design limit of the zuma. Im not an electronics engineer so maybe im doing the wrong thing entirely.
So I guess a follow up question would be: Is the heat okay? Some power bricks get hot when theyre used anyway and its just how they work. This is when i resorted to the math haha, so is the heat okay or a warning sign of the power supply struggling?
Ensure that a minimum of 2 doses of tocilizumab are available for each patient prior to infusion of TECARTUS. Following infusion, monitor patients for signs and symptoms of CRS daily for at least 7 days at the certified healthcare facility, and for 4 weeks thereafter. Counsel patients to seek immediate medical attention should signs or symptoms of CRS occur at any time. At the first sign of CRS, institute treatment with supportive care, tocilizumab, or tocilizumab and corticosteroids as indicated.
Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome (HLH/MAS), including life-threatening reactions, occurred following treatment with TECARTUS. HLH/MAS occurred in 4% (3/78) of patients with ALL. Two patients experienced Grade 3 events and 1 patient experienced a Grade 4 event. The median time to onset for HLH/MAS was 8 days (range: 6 to 9 days) with a median duration of 5 days (range: 2 to 8 days). All 3 patients with HLH/MAS had concurrent CRS symptoms and neurologic events after TECARTUS infusion. Treatment of HLH/MAS should be administered per institutional standards.
Severe Infections: Severe or life-threatening infections occurred in patients after TECARTUS infusion. Infections (all grades) occurred in 56% (46/82) of patients with MCL. Grade 3 or higher infections, including bacterial, viral, and fungal infections, occurred in 30% of patients. TECARTUS should not be administered to patients with clinically significant active systemic infections. Monitor patients for signs and symptoms of infection before and after infusion and treat appropriately. Administer prophylactic antimicrobials according to local guidelines.
Febrile neutropenia was observed in 6% of patients with MCL after TECARTUS infusion and may be concurrent with CRS. In the event of febrile neutropenia, evaluate for infection and manage with broad-spectrum antibiotics, fluids, and other supportive care as medically indicated.
In immunosuppressed patients, life-threatening and fatal opportunistic infections have been reported. The possibility of rare infectious etiologies (e.g., fungal and viral infections such as HHV-6 and progressive multifocal leukoencephalopathy) should be considered in patients with neurologic events and appropriate diagnostic evaluations should be performed.
Hepatitis B virus (HBV) reactivation, in some cases resulting in fulminant hepatitis, hepatic failure, and death, can occur in patients treated with drugs directed against B cells. Perform screening for HBV, HCV, and HIV in accordance with clinical guidelines before collection of cells for manufacturing.
Hypogammaglobulinemia and B-cell aplasia can occur in patients receiving treatment with TECARTUS. Hypogammaglobulinemia was reported in 16% (13/82) of patients with MCL. Monitor immunoglobulin levels after treatment with TECARTUS and manage using infection precautions, antibiotic prophylaxis, and immunoglobulin replacement. The safety of immunization with live viral vaccines during or following TECARTUS treatment has not been studied. Vaccination with live virus vaccines is not recommended for at least 6 weeks prior to the start of lymphodepleting chemotherapy, during treatment, and until immune recovery following treatment with TECARTUS.
Secondary Malignancies may develop. Monitor life-long for secondary malignancies. In the event that one occurs, contact Kite at 1-844-454-KITE (5483) to obtain instructions on patient samples to collect for testing.
Effects on Ability to Drive and Use Machines: Due to the potential for neurologic events, including altered mental status or seizures, patients are at risk for altered or decreased consciousness or coordination in the 8 weeks following TECARTUS infusion. Advise patients to refrain from driving and engaging in hazardous activities, such as operating heavy or potentially dangerous machinery, during this period.
This indication is approved under accelerated approval based on overall response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.
TECARTUS, the Tecartus Logo, YESCARTA, KITE KONNECT, the Kite Konnect Logo, KITE, and the Kite Logo are trademarks of Kite Pharma, Inc. GILEAD is a trademark of Gilead Sciences, Inc. All other trademarks referenced herein are the property of their respective owners.
You are going to a website that contains clinical information and was created specifically for healthcare professionals. If you are not a healthcare professional and would like to return to the consumer site, please click CANCEL.
7fc3f7cf58